Mitumomab

Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.[1]

Mitumomab

Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	GD3 ganglioside
Clinical data
ATC code	none
Identifiers
CAS Number	216503-58-1^N
IUPHAR/BPS	7981
ChemSpider	none
KEGG	D05061^Y
^NY (what is this?)  (verify)

The first phase III clinical trial began in 1998.[2][3] In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.[4][5]

See also

• Anti-ganglioside antibodies

References

1. "Mitumomab - AdisInsight". Adisinsight.springer.com. 2005-06-13. Retrieved 2017-01-06.
2. Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
3. Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
4. Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. (October 2008). "Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer". European Journal of Cancer. 44 (15): 2178–84. doi:10.1016/j.ejca.2008.06.036. PMID 18676140.
5. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. (October 2005). "Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)". Journal of Clinical Oncology. 23 (28): 6854–64. doi:10.1200/JCO.2005.17.186. PMID 16192577.